

Aijaz Ahmed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4124134/publications.pdf>

Version: 2024-02-01

227
papers

11,090
citations

57719

44
h-index

37183

96
g-index

234
all docs

234
docs citations

234
times ranked

12938
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. <i>Gastroenterology</i> , 2015, 148, 547-555.	0.6	1,506
2	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
3	Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.. <i>Hepatology</i> , 2014, 59, 2188-2195.	3.6	616
4	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	2.4	559
5	Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 8263-8276.	1.4	514
6	Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 580-589.e5.	2.4	269
7	Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2062-2070.	2.4	267
8	Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. <i>Journal of Hepatology</i> , 2021, 75, 1284-1291.	1.8	229
9	Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1356-1358.	2.4	200
10	High Prevalence of Concurrent Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: Early Experience From California. <i>Gastroenterology</i> , 2020, 159, 775-777.	0.6	198
11	Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2915-2922.	1.1	192
12	Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. <i>Gastroenterology</i> , 2018, 155, 1154-1163.e3.	0.6	166
13	Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2019, 69, 1064-1074.	3.6	154
14	Transarterial Chemoinfusion for Hepatocellular Carcinoma as Downstaging Therapy and a Bridge toward Liver Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 1158-1168.	2.6	128
15	Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 123-131.e1.	2.4	125
16	Elevated Alpha-Fetoprotein. <i>Clinics in Liver Disease</i> , 2015, 19, 309-323.	1.0	118
17	Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. <i>American Journal of Transplantation</i> , 2019, 19, 1380-1387.	2.6	110
18	Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 544-563.	1.9	108

#	ARTICLE	IF	CITATIONS
19	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	2.4	107
20	Current epidemiology in hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1295-1307.	1.4	107
21	Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. <i>World Journal of Hepatology</i> , 2014, 6, 263.	0.8	99
22	Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3142-3148.	1.1	92
23	The Role of Vitamin E in the Treatment of NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 86.	1.0	87
24	Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2017, 112, 1495-1505.	0.2	83
25	The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 41.	0.7	80
26	Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. <i>Hepatology</i> , 2021, 74, 3316-3329.	3.6	75
27	Current Indications and Contraindications for Liver Transplantation. <i>Clinics in Liver Disease</i> , 2007, 11, 227-247.	1.0	73
28	Telomeres and Telomerase: Basic Science Implications for Aging. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 1105-1109.	1.3	70
29	Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 72, 1556-1568.	3.6	70
30	Early Impact of COVID-19 on Solid Organ Transplantation in the United States. <i>Transplantation</i> , 2020, 104, 2221-2224.	0.5	68
31	COVID-19 and liver injury: a meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 990-995.	0.8	64
32	Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. <i>Hepatology International</i> , 2019, 13, 205-213.	1.9	63
33	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2020, 14, 168-178.	1.4	63
34	Depression is associated with non-alcoholic fatty liver disease among adults in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 590-598.	1.9	62
35	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 743-753.	3.7	60
36	Splenic rupture: an unusual complication of colonoscopy. <i>American Journal of Gastroenterology</i> , 1997, 92, 1201-4.	0.2	59

#	ARTICLE	IF	CITATIONS
37	Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 2155.	0.8	57
38	Ethnic Disparities in the Association of Body Mass Index with the Risk of Hypertension and Diabetes. <i>Journal of Community Health</i> , 2014, 39, 437-445.	1.9	55
39	Nutritional Needs and Support for Children with Chronic Liver Disease. <i>Nutrients</i> , 2017, 9, 1127.	1.7	55
40	Serum testosterone and nonalcoholic fatty liver disease in men and women in the <sc>US</sc>. <i>Liver International</i> , 2018, 38, 2051-2059.	1.9	55
41	Recent Epidemiology of Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2021, 15, 206-216.	1.4	54
42	Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017. <i>Gastroenterology</i> , 2019, 157, 1055-1066.e11.	0.6	53
43	The importance of a multidisciplinary approach to hepatocellular carcinoma. <i>Journal of Multidisciplinary Healthcare</i> , 2017, Volume 10, 95-100.	1.1	52
44	Hepatitis C Virus Infection and Coronary Artery Disease Risk: A Systematic Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1586-1593.	1.1	50
45	Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1121-1128.	0.8	49
46	Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1438-e1455.	2.4	49
47	Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. <i>Liver Transplantation</i> , 2014, 20, n/a-n/a.	1.3	46
48	A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRP β expression. <i>Nature Communications</i> , 2019, 10, 794.	5.8	46
49	Elevated urinary bisphenol A levels are associated with nonalcoholic fatty liver disease among adults in the United States. <i>Liver International</i> , 2019, 39, 1335-1342.	1.9	44
50	Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-9.	0.7	43
51	Improved survival outcomes in patients with nonalcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 <sc>United </sc>network for <sc>Organ </sc>sharing data. <i>Clinical Transplantation</i> , 2014, 28, 713-721.	0.8	42
52	Diabetes Mellitus, and Not Obesity, Is Associated with Lower Survival Following Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1036-1044.	1.1	42
53	Predictors of nonalcoholic steatohepatitis and significant fibrosis in nonobese nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 332-341.	1.9	41
54	Long Term Trends and Racial/Ethnic Disparities in the Prevalence of Obesity. <i>Journal of Community Health</i> , 2014, 39, 1150-1160.	1.9	40

#	ARTICLE	IF	CITATIONS
55	Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. <i>American Journal of Gastroenterology</i> , 2020, 115, 1496-1504.	0.2	40
56	Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1240-1247.e5.	2.4	40
57	Chronic hepatitis C with normal aminotransferase levels. <i>Gastroenterology</i> , 2004, 126, 1409-1415.	0.6	39
58	Association of Digestive Symptoms and Hospitalization in Patients With SARS-CoV-2 Infection. <i>American Journal of Gastroenterology</i> , 2020, 115, 1129-1132.	0.2	39
59	Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways. <i>World Journal of Hepatology</i> , 2015, 7, 2384.	0.8	39
60	Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1499-1501.e2.	2.4	38
61	NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 215-221.	0.7	37
62	Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999, 14, S12-8.	1.4	36
63	Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. <i>Diseases (Basel)</i> , 2020, 10, 1078-1083. <small>1.0</small>	1.0	36
64	The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2019, 7, 27.	1.0	36
65	Association of Sarcopenia and NAFLD: An Overview. <i>Clinical Liver Disease</i> , 2020, 16, 73-76.	1.0	36
66	Low-Normal Thyroid Function Is Associated With Advanced Fibrosis Among Adults in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2379-2381.	2.4	35
67	Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States. <i>Liver International</i> , 2021, 41, 1832-1840.	1.9	35
68	Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 452-453.	2.4	34
69	Incidence of Hepatocellular Carcinoma Among US Patients With Cirrhosis of Viral or Nonviral Etiologies. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1412-1417.	2.4	33
70	Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. <i>Transplant Infectious Disease</i> , 2015, 17, 275-278.	0.7	32
71	Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. <i>Liver International</i> , 2019, 39, 1661-1671.	1.9	32
72	The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 873-880.	1.3	31

#	ARTICLE	IF	CITATIONS
73	Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-5.	0.7	31
74	Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States. <i>PLoS ONE</i> , 2017, 12, e0186702.	1.1	30
75	Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. <i>Journal of Hepatology</i> , 2021, 74, 1355-1361.	1.8	30
76	Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 221-235.	4.5	30
77	Combination of racial/ethnic and etiology/disease-specific factors is associated with lower survival following liver transplantation in African Americans: an analysis from UNOS/OPTN database. <i>Clinical Transplantation</i> , 2014, 28, 755-761.	0.8	29
78	Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges. <i>Hepatology</i> , 2016, 64, 954-954.	3.6	29
79	Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition. <i>MBio</i> , 2020, 11, .	1.8	29
80	Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 965-973.e2.	2.4	28
81	Clinical Presentation and Survival of Asian and Non-Asian Patients with HCV-Related Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2014, 59, 192-200.	1.1	27
82	An Overview of Dietary Interventions and Strategies to Optimize the Management of Non-Alcoholic Fatty Liver Disease. <i>Diseases (Basel, Switzerland)</i> , 2017, 5, 23.	1.0	27
83	Association between cagA negative <i>Helicobacter pylori</i> status and nonalcoholic fatty liver disease among adults in the United States. <i>PLoS ONE</i> , 2018, 13, e0202325.	1.1	26
84	Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. <i>Liver Transplantation</i> , 2020, 26, 68-79.	1.3	26
85	Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality. <i>Liver International</i> , 2020, 40, 815-824.	1.9	26
86	Liver Transplantation: Evolving Patient Selection Criteria. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2001, 15, 729-738.	1.8	25
87	Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-7.	0.7	25
88	Hepatitis C in Pregnancy. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 31.	1.0	25
89	Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis. <i>Liver Transplantation</i> , 2019, 25, 68-78.	1.3	25
90	Implementation and Impact of Universal Preprocedure Testing of Patients for COVID-19 Before Endoscopy. <i>Gastroenterology</i> , 2020, 159, 1586-1588.e4.	0.6	25

#	ARTICLE	IF	CITATIONS
91	Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders. <i>Digestive Diseases and Sciences</i> , 2012, 57, 3011-3016.	1.1	24
92	Mutations in HBV DNA Polymerase Associated With Nucleos(t)ide Resistance Are Rare in Treatment-naïve Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1363-1370.	2.4	24
93	Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. <i>Hepatology</i> , 2017, 66, 46-56.	3.6	24
94	Continuous Positive Airway Pressure Therapy on Nonalcoholic Fatty Liver Disease in Patients With Obstructive Sleep Apnea. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 1315-1322.	1.4	24
95	Leucocyte telomere shortening is associated with nonalcoholic fatty liver disease-related advanced fibrosis. <i>Liver International</i> , 2018, 38, 1839-1848.	1.9	24
96	Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis. <i>Liver Transplantation</i> , 2019, 25, 399-410.	1.3	24
97	Patients with hepatocellular carcinoma from more rural and lower-income households have more advanced tumor stage at diagnosis and significantly higher mortality. <i>Cancer</i> , 2021, 127, 45-55.	2.0	24
98	Long-term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 271-278.	1.9	23
99	Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017. <i>Diabetologia</i> , 2019, 62, 1185-1194.	2.9	23
100	Temporal Trends Associated With the Rise in Alcoholic Liver Disease-related Liver Transplantation in the United States. <i>Transplantation</i> , 2019, 103, 131-139.	0.5	23
101	Management of gallstones and their complications. <i>American Family Physician</i> , 2000, 61, 1673-80, 1687-8.	0.1	23
102	Future Therapy for Hepatitis B Virus: Role of Immunomodulators. <i>Current Hepatology Reports</i> , 2016, 15, 237-244.	0.4	22
103	Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016, 22, 1356-1366.	1.3	22
104	Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2174-2181.	1.1	22
105	Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1282-1289.	1.9	21
106	Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis. <i>Hepatology International</i> , 2019, 13, 84-90.	1.9	21
107	Hepatitis C Treatment Delivery Mandates Optimizing Available Health Care Human Resources. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1947.	3.8	20
108	Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 149-156.	0.8	20

#	ARTICLE	IF	CITATIONS
109	Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. <i>Journal of Gastroenterology</i> , 2020, 55, 330-341.	2.3	20
110	Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2664-2666.e2.	2.4	20
111	Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-5.	0.7	20
112	Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity. <i>Maturitas</i> , 2019, 124, 48-54.	1.0	19
113	Disparate Trends in Mortality of Etiology-Specific Chronic Liver Diseases Among Hispanic Subpopulations. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1607-1615.e2.	2.4	19
114	Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	19
115	Hepatitis E virus infection in the liver transplant recipients: Clinical presentation and management. <i>World Journal of Hepatology</i> , 2016, 8, 117.	0.8	19
116	Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients. <i>Journal of Viral Hepatitis</i> , 2012, 19, e105-11.	1.0	18
117	Short Sleep Duration Is Associated With Abnormal Serum Aminotransferase Activities and Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 588-590.	2.4	18
118	Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 47.	0.7	18
119	Significantly Higher Mortality Following Liver Transplantation Among Patients Aged 70 Years and Older. <i>Progress in Transplantation</i> , 2017, 27, 225-231.	0.4	17
120	Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 93.	1.0	17
121	The Role of Cannabinoids in the Setting of Cirrhosis. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 52.	0.7	17
122	Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 990-1002.	1.1	17
123	Decline in Annual Mortality of Hepatitis C Virus-Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. <i>Gastroenterology</i> , 2020, 159, 1558-1560.e2.	0.6	17
124	Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 839-846.	1.9	16
125	Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 62.	1.0	16
126	Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 62.	1.0	16

#	ARTICLE	IF	CITATIONS
127	PNPLA3 Gene Polymorphism and Liver- and Extrahepatic Cancer-Related Mortality in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1064-1066.	2.4	16
128	Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States. <i>Journal of Viral Hepatitis</i> , 2017, 24, 789-796.	1.0	15
129	Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis. <i>Nutrients</i> , 2017, 9, 1114.	1.7	15
130	Increasing Trends in Transplantation of HCV-Positive Livers Into Uninfected Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1634-1636.	2.4	15
131	Trends in the Mortality of Biliary Tract Cancers Based on Their Anatomical Site in the United States From 2009 to 2018. <i>American Journal of Gastroenterology</i> , 2021, 116, 1053-1062.	0.2	15
132	Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017-2018. <i>Journal of General Internal Medicine</i> , 2022, 37, 261-263.	1.3	15
133	Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-4.	0.7	15
134	Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. <i>World Journal of Gastroenterology</i> , 2018, 24, 315-322.	1.4	15
135	Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States. <i>Clinical Diabetes</i> , 2017, 35, 79-83.	1.2	14
136	Judicious Use of Lipid Lowering Agents in the Management of NAFLD. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 87.	1.0	14
137	Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-4.	0.7	14
138	The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 59-66.	0.7	14
139	Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3552-3557.	1.1	13
140	Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1608-1616.	1.0	13
141	Early Liver Transplantation is a Viable Treatment Option in Severe Acute Alcoholic Hepatitis. <i>Alcohol and Alcoholism</i> , 2018, 53, 716-718.	0.9	13
142	Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease. <i>Journal of Palliative Medicine</i> , 2020, 23, 97-106.	0.6	13
143	Primary Surgical Resection Versus Liver Transplantation for Transplant-Eligible Hepatocellular Carcinoma Patients. <i>Digestive Diseases and Sciences</i> , 2014, 59, 183-191.	1.1	12
144	Disparities in Liver Transplantation Resulting From Variations in Regional Donor Supply and Multiple Listing Practices. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 313-315.	2.4	12

#	ARTICLE	IF	CITATIONS
145	Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1647-1653.	1.1	12
146	High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 900-905.	1.1	11
147	Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 738-746.	1.9	11
148	When to Initiate Weight Loss Medications in the NAFLD Population. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 91.	1.0	11
149	Gender and Racial Differences in Hospitalizations for Primary Biliary Cholangitis in the USA. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1461-1476.	1.1	11
150	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245.	0.5	11
151	Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 457-465.	1.0	11
152	The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes. <i>Journal of Viral Hepatitis</i> , 2016, 23, 53-61.	1.0	10
153	High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population?. <i>Hepatology</i> , 2016, 63, 20-22.	3.6	10
154	The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C. <i>Telemedicine Journal and E-Health</i> , 2017, 23, 870-873.	1.6	10
155	Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease. <i>Diseases (Basel, Switzerland)</i> , 2017, 5, 20.	1.0	10
156	Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3413-3430.	1.1	10
157	Understanding Gaps in the Hepatocellular Carcinoma Cascade of Care. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 850-856.	1.1	10
158	PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1789-1794.	1.4	10
159	New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. <i>World Journal of Gastroenterology</i> , 2021, 27, 4818-4830.	1.4	10
160	Treatment strategies for chronic hepatitis C prior to and following liver transplantation. <i>World Journal of Hepatology</i> , 2016, 8, 69.	0.8	10
161	Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. <i>Transplantation Direct</i> , 2022, 8, e1313.	0.8	10
162	Differential effects of Ca ²⁺ channel blockers on Ca ²⁺ transients and cell cycle progression in vascular smooth muscle cells. <i>European Journal of Pharmacology</i> , 1998, 344, 323-331.	1.7	9

#	ARTICLE	IF	CITATIONS
163	A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 39-41.	1.1	9
164	Pre-Operative Delta-MELD is an Independent Predictor of Higher Mortality following Liver Transplantation. <i>Scientific Reports</i> , 2019, 9, 8312.	1.6	9
165	Gallstone Disease and Its Association With Nonalcoholic Fatty Liver Disease, All-Cause and Cause-Specific Mortality. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 940-948.e2.	2.4	9
166	Association between Sarcopenic Obesity and Nonalcoholic Fatty Liver Disease and Fibrosis detected by Fibroscan. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 227-232.	0.5	8
167	Underutilization of Living Donor Liver Transplantation in the United States: Bias against MELD 20 and Higher. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 169-174.	0.7	8
168	<scp>HCV</scp> infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States. <i>Clinical Transplantation</i> , 2015, 29, 920-926.	0.8	7
169	Case Report of Isoniazid-Related Acute Liver Failure Requiring Liver Transplantation. <i>Diseases (Basel)</i> , 2021, 11, 1077. <small>Tj ETQq1 1 0.784314 rgBT /Over</small>	1.0	7
170	Association between advanced fibrosis in fatty liver disease and overall mortality based on body fat distribution. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 90-96.	1.4	7
171	Longitudinal Change in Thyroid-Stimulating Hormone and Risk of Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 848-849.e1.	2.4	7
172	Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. <i>Hepatology Communications</i> , 2021, 5, 516-525.	2.0	7
173	Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents. <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 1-5.	0.7	7
174	Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD. <i>Hepatology Communications</i> , 2022, 6, 1516-1526.	2.0	7
175	Hepatic encephalopathy: what the multidisciplinary team can do. <i>Journal of Multidisciplinary Healthcare</i> , 2017, Volume 10, 113-119.	1.1	6
176	Hepatocellular carcinoma is leading in cancer-related disease burden among hospitalized baby boomers. <i>Annals of Hepatology</i> , 2019, 18, 679-684.	0.6	6
177	Increasing Mortality Among Patients With Diabetes and Chronic Liver Disease From 2007 to 2017. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 992-994.	2.4	6
178	Trends in Hospitalizations for Clostridioides difficile Infection in End-Stage Liver Disease, 2005-2014. <i>Digestive Diseases and Sciences</i> , 2021, 66, 296-307.	1.1	6
179	Cost-effective evaluation of acute viral hepatitis. <i>Western Journal of Medicine</i> , 2000, 172, 29-32.	0.3	6
180	Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-4.	0.7	6

#	ARTICLE	IF	CITATIONS
181	A fatal case of <i>Rhodotorula meningitis</i> in AIDS. <i>Medicine and Health, Rhode Island</i> , 1998, 81, 22-3.	0.1	6
182	Trends in Liver Transplantation Multiple Listing Practices Associated With Disparities in Donor Availability: An Endless Pursuit to Implement the Final Rule. <i>Gastroenterology</i> , 2016, 151, 382-386.e2.	0.6	5
183	Extrahepatic Manifestations of Hepatitis C Virus After Liver Transplantation. <i>Clinics in Liver Disease</i> , 2017, 21, 595-606.	1.0	5
184	Direct-Acting Antiviral Therapy and Improvement in Graft Survival of Hepatitis C Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, e349.	0.5	5
185	Rates of liver retransplantation in the United States are declining in the era of direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1194-1195.	1.0	5
186	Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary. <i>Nutrition and Metabolic Insights</i> , 2019, 12, 117863881984748.	0.8	5
187	Treatment of inoperable hepatocellular carcinoma with immunotherapy. <i>BMJ Case Reports</i> , 2019, 12, e229744.	0.2	5
188	Association of Anti-TNF Therapy With Increased Risk of Acute Cholangitis in Patients With Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1602-1609.	0.9	5
189	The impact of chronic liver disease in patients receiving active pharmacological therapy for opioid use disorder: One-year findings from a prospective cohort study. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107917.	1.6	5
190	The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 477-482.	1.3	5
191	Trends in the Prevalence of Hepatitis C Virus Infection based on the Insurance Status in the United States from 2013 to 2018. <i>Liver International</i> , 2022, 42, 340-349.	1.9	5
192	Renal Artery Stenosis in Patients with Peripheral Vascular Disease in Kuwait. <i>Medical Principles and Practice</i> , 2005, 14, 386-389.	1.1	4
193	Task-shifting – A practical strategy to improve the global access to treatment for chronic hepatitis C. <i>International Journal of Nursing Studies</i> , 2016, 62, 168-169.	2.5	4
194	Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United States. <i>Journal of General Internal Medicine</i> , 2018, 33, 1423-1425.	1.3	4
195	Prevalence and risk factors of erectile dysfunction among patients attending primary health care centres in Qatar. <i>Eastern Mediterranean Health Journal</i> , 2011, 17, 587-92.	0.3	4
196	Trends in All-Cause and Cause-Specific Mortality Among Individuals With Diabetes Before and During the COVID-19 Pandemic in the U.S.. <i>Diabetes Care</i> , 2022, 45, e107-e109.	4.3	4
197	Impact of sarcopenia on the progression of nonalcoholic fatty liver disease: a frequently forgotten association. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 260-261.	0.7	3
198	Economic burden and healthcare utilization in nonalcoholic fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 181-183.	0.7	3

#	ARTICLE	IF	CITATIONS
199	Treating Alcohol Use Disorder in Chronic Liver Disease. <i>Clinical Liver Disease</i> , 2020, 15, 77-80.	1.0	3
200	Posttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non-“Hepatocellular Carcinoma Factors. <i>Liver Transplantation</i> , 2021, 27, 684-698.	1.3	3
201	Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 16-22.	0.7	3
202	Extrahepatic causes of death in cirrhosis compared to other chronic conditions in the United States, 1999-2017. <i>Annals of Hepatology</i> , 2021, 26, 100565.	0.6	3
203	Nonalcoholic fatty liver disease in early life and all-cause and cause-specific mortality. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 317-319.	0.7	3
204	Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. <i>Adolescent Health, Medicine and Therapeutics</i> , 2018, Volume 9, 103-110.	0.7	2
205	Current Trends in Liver Transplantation for Alcoholic Hepatitis. <i>Clinics in Liver Disease</i> , 2021, 25, 625-634.	1.0	2
206	Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 747-756.	1.1	2
207	Reply: NAFLD Vs MAFLD “It is not the name but the disease that decides the outcome in fatty liver. <i>Journal of Hepatology</i> , 2021, , .	1.8	2
208	Prevalence and Risk Factors for Falls Among the Elderly in Primary Healthcare Centers (PHC) in Qatar. <i>Qatar Medical Journal</i> , 2011, 2011, .	0.2	1
209	Indications for antiviral therapy for chronic hepatitis B in pregnant mothers. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217232.	0.2	1
210	Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-3.	0.2	1
211	Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-“Infected Donors for Uninfected Recipients. <i>Hepatology</i> , 2018, 68, 792-793.	3.6	1
212	Genetic Factors and Continental Ancestry Account for Some Disparities in Nonalcoholic Fatty Liver Disease Among Hispanic Subgroups. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2176-2178.	2.4	1
213	Regional Trends in Mortality from Alcohol-Induced Causes in the United States, 2000-“2017. <i>Journal of General Internal Medicine</i> , 2020, 35, 2495-2498.	1.3	1
214	Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-“transplant Clinical Outcome. <i>Clinical Transplantation</i> , 2020, 34, e14128.	0.8	1
215	Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B. <i>Gut</i> , 2020, 69, 2054-2056.	6.1	1
216	Recent advances in liver transplantation with HCV seropositive donors. <i>F1000Research</i> , 2019, 8, 2151.	0.8	1

#	ARTICLE	IF	CITATIONS
217	The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States. <i>Annals of Gastroenterology</i> , 2022, 35, 194-202.	0.4	1
218	Hemorrhagic Ascites Is Associated With Reduced Survival in Cirrhosis: A Systematic Review and Meta-Analysis. <i>Gastroenterology Research</i> , 2022, 15, 26-32.	0.4	1
219	Update on chronic hepatitis C. <i>Comprehensive Therapy</i> , 2003, 29, 224-232.	0.2	0
220	Hepatitis C Virus Infection. , 0, , 2139-2166.		0
221	Optimal timing for hepatitis C antiviral therapy in the peritransplant period?. <i>Hepatology</i> , 2017, 66, 1004-1004.	3.6	0
222	Reply. <i>Hepatology</i> , 2018, 67, 450-451.	3.6	0
223	Road to identifying endpoint biomarkers in the treatment of nonalcoholic steatohepatitis: are we there yet?. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 244-246.	0.7	0
224	Trends in mortality in hepatitis C infection and alcoholic liver disease based on drug overdose in the United States. <i>Journal of Viral Hepatitis</i> , 2021, 28, 436-439.	1.0	0
225	681â€fIncreasing Representation in Surgical Careers â€“ the First Cut Mentorship Programme for Medical Students. <i>British Journal of Surgery</i> , 2021, 108, .	0.1	0
226	Comparable survival for hepatitis C-related hepatocellular carcinoma after liver transplantation irrespective of viremic status. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
227	Hepatitis C Virus Infection. , 0, , 642-647.		0